[The problem of side effects after a treatment with L-dopa in the Parkinson's syndrome: clinical and animal studies (author's transl)].
D000328:Adult; D000368:Aged; D001921:Brain / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000139:chemically induced; D004298:Dopamine / Q000378:metabolism; D003875:Drug Eruptions; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced; D010292:Paresthesia / Q000139:chemically induced; D010302:Parkinson Disease, Secondary / Q000150:complications / Q000188:drug therapy*; D011605:Psychoses, Substance-Induced
D007980:Levodopa; D004298:Dopamine
El problema de las acciones secundarias de la L dopa en el tratamiento del síndrome de Parkinson en sus aspectos clínicos y experimentales sobre animales